论文部分内容阅读
乳腺癌具有高度异质性,即使组织学类型、临床分期、治疗模式均相同,预后也存在着较大的差别。这使人们认识到,传统的乳腺癌病理分型已经不能完全适应乳腺癌的诊断,特别是个体化治疗的需要。随着分子生物学理论和技术的发展、乳腺癌基因芯片技术的应用,乳腺癌分子分型方法应运而生。由于其更加适应临床治疗及预后评估的需要,被越来越多的人所接受。基底细胞样乳腺癌(BLBC)作为乳腺癌分子分型的一个亚型,以其独特的临床表现、免疫表型及不良预后引起国内外学者的高度关注。本文从BLBC的免疫表型、临床病理特征、分子生物学和遗传学及治疗和预后方面做一综述,以进一步了解其研究进展。
Breast cancer has a high degree of heterogeneity, even if the histological type, clinical stage, treatment patterns are the same, the prognosis there is a big difference. This makes people realize that the traditional pathological classification of breast cancer can not completely adapt to the diagnosis of breast cancer, especially the need for individualized treatment. With the development of molecular biology theory and technology, the application of breast cancer gene chip technology and the molecular typing of breast cancer came into being. Because of its more suitable for clinical treatment and prognosis assessment needs, more and more people are accepted. As a subtype of breast cancer, basal cell-like breast cancer (BLBC) is of great concern to both domestic and foreign scholars for its unique clinical manifestations, immunophenotypes and poor prognosis. This review summarizes the immunophenotypes, clinical and pathological features, molecular biology and genetics, and treatment and prognosis of BLBC to further understand its research progress.